Lessee, Operating Lease, Liability, to be Paid in USD of PROVECTUS BIOPHARMACEUTICALS, INC. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease.
Summary
Provectus Biopharmaceuticals, Inc. quarterly Lessee, Operating Lease, Liability, to be Paid history and change rate from Q1 2019 to Q3 2025.
  • Provectus Biopharmaceuticals, Inc. Lessee, Operating Lease, Liability, to be Paid for the quarter ending September 30, 2025 was $149K, a 287% increase year-over-year.
Lessee, Operating Lease, Liability, to be Paid, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, YoY Quarterly Change (%)

PROVECTUS BIOPHARMACEUTICALS, INC. Quarterly Lessee, Operating Lease, Liability, to be Paid (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $149K +$110K +287% Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $162K +$111K +216% Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $12.8K -$51K -79.9% Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $25.7K -$50.7K -66.4% Dec 31, 2024 10-K 2025-03-28
Q3 2024 $38.5K -$50.3K -56.7% Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $51.3K -$50K -49.3% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $63.8K -$49.6K -43.8% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $76.3K -$49.3K -39.2% Dec 31, 2023 10-K 2024-03-28
Q3 2023 $88.8K -$49K -35.5% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $101K -$48.6K -32.4% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $113K +$95K +515% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $126K +$79K +169% Dec 31, 2022 10-K 2023-03-30
Q3 2022 $138K +$72.7K +112% Sep 30, 2022 10-Q 2022-11-09
Q2 2022 $150K Jun 30, 2022 10-Q 2022-08-11
Q1 2022 $18.4K -$97.8K -84.1% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 $46.7K -$92.5K -66.5% Dec 31, 2021 10-K 2022-03-29
Q3 2021 $65.1K -$96.9K -59.8% Sep 30, 2021 10-Q 2021-11-10
Q1 2021 $116K -$91.1K -43.9% Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $139K -$90.7K -39.5% Dec 31, 2020 10-K 2021-03-02
Q3 2020 $162K -$92.5K -36.3% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $185K -$58.1K -23.9% Jun 30, 2020 10-Q 2020-08-12
Q1 2020 $207K -$53.7K -20.6% Mar 31, 2020 10-Q 2020-05-13
Q4 2019 $230K Dec 31, 2019 10-K 2020-03-05
Q3 2019 $255K Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $243K Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $261K Mar 31, 2019 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.